Omacetaxine mepesuccinate (formerly homoharringtonine) is a molecule with a mechanism of action that is different from tyrosine kinase inhibitors, and its activity in chronic myeloid leukemia (CML) seems to be independent of the BCR-ABL mutation status. Using BCR-ABL-expressing myelogenous and lymphoid cell lines and mouse models of CML and B-cell acute lymphoblastic leukemia (B-ALL) induced by wild-type BCR-ABL or T315I mutant-BCR-ABL, we evaluated the inhibitory effects of omacetaxine on CML and B-ALL. We showed that more than 90% of the leukemic stem cells were killed after treatment with omacetaxine in vitro. In contrast, less than 9 or 25% of the leukemic stem cells were killed after treating with imatinib or dasatinib, respectively. After 4 days of treatment of CML mice with omacetaxine, Gr-1 þ myeloid leukemia cells decreased in the peripheral blood of the treated CML mice. In the omacetaxinetreated B-ALL mice, only 0.8% of the B220 þ leukemia cells were found in peripheral blood, compared with 34% of the B220 þ leukemia cells in the placebo group. Treatment with omacetaxine decreased the number of leukemia stem cells and prolonged the survival of mice with BCR-ABL-induced CML or B-ALL.
Introduction
The Abl tyrosine kinase inhibitors (TKIs), imatinib mesylate and dasatinib, have revolutionized the treatment of Philadelphiapositive (Ph þ ) leukemia in both chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL) by targeting and disabling the proliferative signal from BCR-ABL. These TKIs elicit high rates of durable complete cytogenetic responses, particularly in CML; however, only a small proportion of treated individuals remain disease-free if therapy is discontinued. 1, 2 This lack of curative effect of TKIs in Ph þ leukemias is largely because of the insensitivity of primitive leukemic stem cells to these TKIs and the selection of cells expressing TKIresistant BCR-ABL mutants. 3 At present, an anti-stem cell strategy has not been developed for treating these leukemia patients; however, a number of agents, such as farnesyl transferase inhibitors, have shown activity towards leukemic stem cells that is superior to TKIs. 4, 5 These findings suggest that non-TKI-based therapies may prove useful in targeting leukemic stem cells in Ph þ leukemias and raise the prospect of improved rates of durable complete molecular remission.
Omacetaxine is a cephalotaxine ester derived from the evergreen tree, Cephalotaxus harringtonia, native to China. The chemical structure of omacetaxine is shown in Figure 1 . Omacetaxine has shown clinical activity alone and in combination with imatinib in CML patients resistant to imatinib or other TKIs. [6] [7] [8] However, little is known about whether omacetaxine has an inhibitory effect on leukemic stem cells. In this study, we used a mouse model of BCR-ABL-induced leukemia to investigate the efficacy of omacetaxine towards leukemic stem cells. We show that omacetaxine inhibited the proliferation of CML and B-ALL stem cells and provided a significant survival benefit to mice with CML and B-ALL.
Materials and methods

Cell lines
Human K562 myeloid leukemia cell line was grown in RPMI 1640 medium containing 10% FCS. To generate the BCR-ABLexpressing pre-B cell lines, bone marrow cells were transduced with the BCR-ABL-WT or BCR-ABL-T315I-IRES-GFP-MSCV retrovirus followed by transplantation into recipient mice. The BCR-ABL-expressing cells were isolated from the spleen of a mouse with BCR-ABL-induced B-ALL, and pre-B leukemic cells were selected through green fluorescence protein (GFP) sorting by fluorescence-activated cell sorter (FACS). To generate the BCR-ABL-expressing 32D line, the cells were transduced with the BCR-ABL-WT-or BCR-ABL-T315I-IRES-GFP-MSCV retrovirus, and the BCR-ABL-expressing cells were selected by GFP sorting by FACS.
Histology
The lungs from the placebo-or drug-treated mice were fixed in Bouin fixative (Fisher Scientific, Pittsburgh, PA, USA) for 24 h at room temperature followed by an overnight rinse in water. Sections of 10 mm were stained with hematoxylin and eosin and observed under a model DMRE compound microscope (Leica, Heidelberg, Germany). All the sections were imaged with a Â 2.5PH1 objective (NPLan, NA 0.25, Leica) and a Â 10PH1 objective (NPLan, NA 0.40 Leica). All images were imported into MetaMorph software (Molecular Devices, Downingtown, PA, USA) as a series of tagged image files. All images were then constructed in Adobe Photoshop 7.0 (Adobe, San Jose, CA, USA). 
Antibodies and western blot analysis
Antibodies against c-ABL, Hsp90, Hsp70, Mcl-1 and Actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Protein lysates were prepared by lysing cells in radioimmunoprecipitation buffer, and immunoprecipitation and western blotting were carried out as described earlier. 9 
Bone marrow transduction/transplantation
The retroviral vector MSCV-IRES-EGFP 10 carrying the p210 BCR-ABL cDNA was used to make high-titer, helper-free, replication-defective ecotropic virus stock by transient transfection of 293T cells using the kat system 11 as described earlier. 9 6-to 10-week-old wild-type BABL/c or C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used for leukemogenesis experiments. Induction of CML 9 and B-ALL 
Flow cytometry
Hematopoietic cells were collected from the peripheral blood and bone marrow of diseased mice, and red blood cells were lysed with NH 4 Cl red blood cell lysis buffer (pH 7.4). The cells were washed with phosphate-buffered saline, and stained with B220-PE for B cells, Gr-1-APC for neutrophils and Sca1-APC/ c-Kit-PE for hematopoietic stem cells. After staining, the cells were washed once with phosphate-buffered saline and subjected to FACS analysis.
Culture of leukemia stem cells
Bone marrow cells isolated from CML mice were cultured in vitro in the presence of stemspan SFEM, SCF, IGF-2, TPO, heparin and FGF as reported earlier for culture of hematopoietic stem cells.
13,14
Drug treatment
Omacetaxine (ChemGenex Pharmaceuticals, Inc., Menlo Park, CA, USA) was dissolved in 0.9% NaCl to a stock concentration of 1 mg/ml. Further dilutions were made to working concentrations using media or water. Imatinib was dissolved in water directly at a concentration of 10 mg/ml. The drugs were given either by oral gavage for the CML model or by I.P. route for the B-ALL model in a volume of o0.5 ml, once a day, at 0.5 mg or 1.0 mg per kilogram of body weight for omacetaxine and 100 mg per kilogram of body weight per dose of imatinib, beginning at 10 days after bone marrow transplantation (BMT).
Statistical analysis
Results are reported as mean ± s.d. Differences were evaluated by t-test or analysis of variance, and accepted as significance when P-value is less than 0.05.
Results
Omacetaxine suppresses myeloid leukemic cells and improves survival of mice with BCR-ABL-induced CML
To investigate the therapeutic effect of omacetaxine (Supplementary Figure 1 ) on CML, we used a BMT mouse model of CML in which bone marrow cells from BALB/c donor mice pretreated with 5-fluorouracil (5-FU) were transduced with BCR-ABL and injected into BALB/c recipient mice to induce CML. 9 Mice transplanted with BCR-ABL-transduced bone marrow were treated with a placebo or omacetaxine. Omacetaxine treatment of CML mice decreased BCR-ABL-expressing (GFP þ ) leukemia cells during therapy (Figures 1a and b , Po0.001). In addition, splenomegaly in omacetaxine-treated mice (a consistent physical sign in CML) decreased by 88%, compared with placebo ( Figure 1b) . All placebo-treated mice developed CML and died within 3 weeks after BMT. In contrast, all omacetaxine-treated CML mice survived (Figure 1c ). Lung hemorrhage caused by infiltration of mature myeloid leukemia cells is a major cause of death of CML mice. 9 We further evaluated the therapeutic effect of omacetaxine on CML by examining the severity of lung hemorrhages at day 14 after BMT. Compared with placebotreated mice, much less severe hemorrhages were observed in the lungs of omacetaxine-treated CML mice (Figure 1d) . We compared the effect of omacetaxine on BCR-ABL-expressing and non-BCR-ABL-expressing 32D cells, and found that omacetaxine inhibited BCR-ABL-expressing cells more strongly than non-BCR-ABL-expressing cells (Figure 1e ).
Omacetaxine suppresses CML stem cells in vitro and in vivo
Although imatinib, the BCR-ABL inhibitor, has been shown to prolong survival of mice with BCR-ABL-induced CML, it does not completely stop the progression of CML in our BMT mouse model, owing to the accumulation of surviving leukemia stem cells. 15, 16 The Lin À cKit þ Sca-1 þ population has been identified as CML stem cells, as these cells confer leukemia in recipient mice in the CML model. 16 To investigate whether omacetaxine has an inhibitory effect on leukemia stem cells, bone marrow cells from CML mice on day 13 after BMT were isolated and treated with omacetaxine ( Supplementary Figure 2) at various doses in conditions that support survival and growth of hematopoietic stem cells (Figure 2a) . 13, 14 After 6 days in culture, survival of GFP þ Lin À cKit þ Sca-1 þ cells representing leukemia stem cells, as well as of GFP þ cells indicating BCR-ABL-expressing cells, was determined. FACS analysis showed that, compared with the placebo group, omacetaxine treatment inhibited survival of BCR-ABL-expressing leukemia stem cells and total leukemia cells in a dose-dependent manner (Figure 2b , Po0.001).
The effect of omacetaxine on leukemia stem cells in CML mice was also examined. Mice with BCR-ABL-induced CML were treated with a placebo, omacetaxine, imatinib or both drugs in combination for 4 days from day 10 after BMT, and the number of GFP þ Lin À cKit þ Sca-1 þ and total GFP þ bone marrow cells was determined by flow cytometry. Consistent with our earlier findings, 17 imatinib treatment did not lower the percentage and number of leukemia stem cells and total leukemia cells in the bone marrow compared with the placebo group. Omacetaxine treatment greatly reduced the numbers of both leukemia stem cells and total leukemia cells, whereas the treatment of CML mice with both drugs did not show further effects on reducing the number of leukemia stem cells or total leukemia cells, compared with the mice treated with omacetaxine alone (Figure 2c) . The effect of omacetaxine on leukemia stem cells in CML mice was also compared with the effect of omacetaxine on BCR-ABL-negative stem cells in the same animals. We found that a higher percentage of leukemia stem cells were inhibited by omacetaxine as compared with the percent reduction of BCR-ABL-negative stem cells (Figure 2d ).
Omacetaxine improves survival of mice with BCR-ABL-T315I induced CML and suppresses BCR-ABL-T315I leukemia stem cells
Imatinib does not suppress leukemia cells expressing BCR-ABL-T315I and does not prolong the survival of mice with BCR-ABL-T315I-induced CML. [17] [18] [19] To investigate whether omacetaxine also inhibits BCR-ABL-T315I-induced CML and leukemia stem cells, we transduced bone marrow cells with BCR-ABL-T315I and implanted the transduced cells into BALB/c recipient mice to induce CML. Similar to wild-type BCR-ABL-induced CML, omacetaxine caused a decrease in the peripheral blood BCR-ABL-T315I-expressing (GFP þ ) leukemia cells ( Figure 3a ) and reduced splenomegaly (data not shown). BCR-ABL-T315I-expressing myeloid leukemic cells in the peripheral blood of the treated CML mice were reduced greater than 49.5-fold compared with untreated CML mice (Figure 3a) , whereas wildtype BCR-ABL-expressing myeloid leukemic cells in the peripheral blood of the treated CML mice were reduced only 30.2 fold (Figure 1b) . These results suggest that omacetaxine was more efficient in inhibiting BCR-ABL-T315I compared with wild-type BCR-ABL, which is supported by an earlier report. 20 Omacetaxine treatment prolonged the survival of mice transplanted with BCR-ABL-T315I-expressing bone marrow cells (Figure 3b) . We next examined whether omacetaxine could inhibit the BCR-ABL-T315I-induced leukemia stem cells in vivo.
Mice with BCR-ABL-T315I-induced CML were treated with a placebo or omacetaxine for 4 days from day 10 after BMT. Bone marrow and spleen cells were analyzed by FACS for GFP þ Lin 
Omacetaxine inhibits leukemic stem cells and BCR-ABL-induced leukemia in mice
The number of BCR-ABL-T315I-expressing leukemia stem cells was significantly decreased by omacetaxine treatment (Figure 3c ).
Omacetaxine caused degradation of BCR-ABL protein through inhibiting HSP90 and reduced MCL-1 protein level in myeloid leukemic cells
To understand the possible mechanisms by which omacetaxine inhibits myeloid leukemia cells, we examined the effect of omacetaxine on human myeloid leukemia cells (K562). In a dose-dependent manner, treatment with omacetaxine significantly suppressed K562 cell growth, particularly at concentrations of 200 nM or more (Po0.001) (Figure 4a ). We then compared protein levels in K562 cells after treatment with either 50 or 150 nM omacetaxine. After treatment, the levels of BCR-ABL protein were decreased in K562 cells in a dose-dependent manner ( Figure 4b ). As BCR-ABL protein is associated with HSP90 protein, 17 we next measured the HSP90 protein levels and found that the HSP90 protein levels were also decreased after omacetaxine treatment (Figure 4b ). However, HSP70, which plays a positive role in BCR-ABL-mediated resistance to apoptosis, was not changed after omacetaxine treatment (Figure 4b) . Downregulation of MCL-1, a member of the BCL-2 family, is associated with a substantial decrease in viability of K562 cells and reduced survival of imatinib-resistant K562 cells. 21 The level of MCL-1 protein was also greatly reduced after treatment with 150 nM omacetaxine (Figure 4b ).
Omacetaxine improves survival of mice with BCR-ABL-induced B-ALL
In contrast to CML (Figure 1) , the development of B-ALL induced by BCR-ABL is not significantly affected by TKIs such as imatinib and dasatinib. 19, 21 To induce B-ALL in mice, BCR-ABLtransduced bone marrow cells from donor mice that were not pretreated with 5-FU were transplanted into B6 mice. 9, 15 To determine whether omacetaxine was effective in treating B-ALL, we used the B-ALL model, in which pre-B cells express the B220 and CD19 cell surface antigens, and phenotypically resemble de novo Ph þ B-ALL and lymphoid blast crisis of CML. 9,12 These mice were treated with a placebo, 0.5 or 1 mg/kg omacetaxine daily starting at day 10. After 4 days of treatment, only 2% of cells in the peripheral blood were GFP þ B-leukemia cells in the 1 mg/kg group, compared with 20% of the GFP þ B-leukemia cells in the 0.5 mg/kg group or 50% of the GFP þ B-leukemia cells in the placebo group (Po0.001, Figures 5a and b) . After 10 days of treatment, less than 2% of the GFP þ B-leukemia cells were detected in both drug treatment groups (Figures 5a and b) (Po0.001). All the placebo-treated recipients of BCR-ABLtransduced bone marrow developed and died of B-ALL within 4 weeks after BMT (Figure 5c ) and all B-ALL mice treated with omacetaxine survived.
Omacetaxine inhibits BCR-ABL expression without affecting HSP90 in B-lymphoid cells expressing BCR-ABL
We further investigated whether omacetaxine also affected the expression levels of BCR-ABL and HSP90 proteins in lymphoid cells expressing BCR-ABL. Pre-B cells expressing BCR-ABL or BCR-ABL-T315I from omacetaxine-treated B-ALL mice showed a concentration-dependent inhibition of cell proliferation in response to omacetaxine (Figure 6a ). We then compared BCR-ABL protein levels between the placebo and omacetaxine (50 or 150 nM) treatment groups. After the treatment, the level of wildtype BCR-ABL protein was slightly lower in the omacetaxinetreated B-leukemia cells, but the level of BCR-ABL-T315I protein was markedly decreased. However, unlike myeloid leukemia cells (Figure 4b ), the level of HSP90 protein did not change after omacetaxine treatment (Figure 6b ).
Discussion
The BCR-ABL-positive leukemia stem cell is a major target for curative therapy of Ph þ leukemias. 3 Although current TKI-based therapies have significant clinical efficacy in Ph þ leukemias, these agents do not effectively kill BCR-ABL-positive leukemia stem cells and only rarely elicit long-lasting complete cytogenetic remission after cessation of therapy. 1, 2 This finding has led to the investigation of therapeutics that selectively kill BCR-ABL-positive leukemia stem cells as potential novel treatments of Ph þ leukemias. 4, 5 Here, we have shown in animal models of Ph þ CML and B-ALL that omacetaxine effectively targets BCR-ABL-positive leukemia stem cells in vivo and confers a significant survival benefit for leukemic mice. In contrast, earlier work has shown that the TKI imatinib did not affect the numbers of stem cells found in the circulation or the bone marrow of mice with CML. 16 These findings raise the possibility that the clinical efficacy of omacetaxine in CML (where it is currently in phase 2/3 trials) may be due, at least in part, to its inhibiting activity on leukemic stem cells.
The appearance of mutations in the BCR-ABL oncoprotein is a major cause of failure with imatinib therapy of BCR-ABL- Omacetaxine inhibits leukemic stem cells and BCR-ABL-induced leukemia in mice Y Chen et al positive leukemias. 22 Although the second generation TKIs dasatinib and nolotinib inhibit many imatinib resistant mutant BCR-ABL proteins, cells expressing T315I mutant BCR-ABL are resistant to all the three TKIs currently used to treat CML. Ongoing clinical trials have found that omacetaxine has clinical efficacy in CML patients with T315I mutant BCR-ABL. 8 Here, we have shown that omacetaxine significantly prolonged survival in these mice and dramatically reduced the number of T315I BCR-ABL-positive leukemic cells both in vivo and in vitro. These observations support the clinical use of omacetaxine in CML patients with TKI-resistant disease mediated by the T315I mutant BCR-ABL.
The mechanisms for omacetaxine inhibition of Ph þ leukemic stem cells are unclear. As omacetaxine is an inhibitor of protein synthesis, we hypothesized that the anti-leukemic activity of omacetaxine may be because of the loss of anti-apoptotic proteins. We postulated that omacetaxine may induce apoptosis in BCR-ABL-positive CML cells through three potential pathways: (a) by directly reducing the expression of BCR-ABL, (b) by reducing the expression levels of BCR-ABL-stabilizing proteins (such as HSP90), which will lead to the degradation of BCR-ABL and (c) by reducing the expression of the short-lived anti-apoptotic BCL-2 family protein MCL-1. We investigated the effect of omacetaxine on the expression of the BCR-ABL, HSP90 and MCL-1 proteins in CML-derived K562 cells and found that omacetaxine treatment induces the loss of BCR-ABL, HSP90 and MCL-1. These observations are consistent with the hypothesis that omacetaxine acts by directly or indirectly inhibiting the BCR-ABL, MCL-1 and HSP90 pathways in BCR-ABL-positive CML cells and raise the possibility that omacetaxine acts on CML leukemic stem cells through reduced levels of these proteins.
Acute lymphocytic leukemia in adults is commonly caused by the expression of BCR-ABL. In general, B-ALL tends to show different symptoms when compared with CML. Omacetaxine removed most of the GFP þ B220 þ cells from the peripheral blood with less than 1% of GFP þ B220 þ cells still detected by FACS, and prolonged the survival of B-ALL mice. However, there was no change in HSP90 protein levels, although the BCR-ABL protein level was greatly reduced by omacetaxine. In CML, treatment with omacetaxine reduced the level of both HSP90 and the BCR-ABL protein showing a different role for omacetaxine in treating CML and B-ALL. These results are consistent with our earlier observation that BCR-ABL uses different signaling pathway to induce CML and B-ALL. 15 Omacetaxine also has potential for treating CML and Ph Omacetaxine inhibits leukemic stem cells and BCR-ABL-induced leukemia in mice Y Chen et al
